doi: 10.1177/10398562211059086.
Epub 2021 Dec 1.
Long-acting injectable buprenorphine - 'best practice' opioid agonist therapy for Australian prisoners
Affiliations
- PMID: 34852654
- DOI: 10.1177/10398562211059086
Item in Clipboard
Long-acting injectable buprenorphine - 'best practice' opioid agonist therapy for Australian prisoners
Australas Psychiatry.
2022 Aug.
Abstract
Objective: To consider opioid agonist therapy in prisons.
Conclusions: Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as 'best practice' treatment in Australian prison populations.
Keywords: buprenorphine; injectable; long-acting; opioid therapy; prisoners.
Similar articles
-
Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open-label, non-randomised trial of long-acting injectable buprenorphine treatment in Australian custodial settings.Drug Alcohol Rev. 2025 Feb;44(2):640-648. doi: 10.1111/dar.14005. Epub 2025 Feb 3. Drug Alcohol Rev. 2025. PMID: 39901317 Free PMC article. Clinical Trial.
-
Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.Drug Alcohol Depend. 2015 Nov 1;156:133-138. doi: 10.1016/j.drugalcdep.2015.09.001. Epub 2015 Sep 7. Drug Alcohol Depend. 2015. PMID: 26409751 Free PMC article. Clinical Trial.
-
Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.JAMA Netw Open. 2021 Dec 1;4(12):e2138807. doi: 10.1001/jamanetworkopen.2021.38807. JAMA Netw Open. 2021. PMID: 34905010 Free PMC article.
-
Use and misuse of opioid agonists in opioid addiction.Cleve Clin J Med. 2017 May;84(5):377-384. doi: 10.3949/ccjm.84a.16091. Cleve Clin J Med. 2017. PMID: 28530896 Review.
-
[New slow-release buprenorphine formulations for optimization of opioid substitution].Nervenarzt. 2019 Sep;90(9):932-937. doi: 10.1007/s00115-019-0783-6. Nervenarzt. 2019. PMID: 31399813 Review. German.
Cited by
-
Using the stress-vulnerability model to better understand suicide in prison populations.Psychiatr Psychol Law. 2022 Feb 15;30(3):299-333. doi: 10.1080/13218719.2021.2013340. eCollection 2023. Psychiatr Psychol Law. 2022. PMID: 37346061 Free PMC article.
-
Using the Alcohol, Smoking and Substance Involvement Screening Test to predict substance-related hospitalisation after release from prison: A cohort study.Addiction. 2024 Feb;119(2):236-247. doi: 10.1111/add.16365. Epub 2023 Oct 19. Addiction. 2024. PMID: 37855049 Free PMC article.
-
Case report: Local anesthesia with lidocaine infiltration for extended-release buprenorphine therapy.Front Psychiatry. 2025 Jan 23;16:1500799. doi: 10.3389/fpsyt.2025.1500799. eCollection 2025. Front Psychiatry. 2025. PMID: 39916746 Free PMC article.
-
The predictive validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for moderate- to high-risk cannabis, methamphetamine and opioid use after release from prison.Addiction. 2023 Jun;118(6):1107-1115. doi: 10.1111/add.16138. Epub 2023 Feb 6. Addiction. 2023. PMID: 36680769 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
